Study shows medical cannabis effective in treating a wide range of health conditions

September 11, 2018, University of New Mexico
A new study demonstrates the effectiveness of medical cannabis on a wide range of health conditions. Credit: University of New Mexico stock image

Utilizing new mobile application technology, researchers at The University of New Mexico found that medical cannabis provides immediate symptom relief across dozens of health symptoms with relatively minimal negative side effects.

In two recent studies titled, "Patient-Reported Symptom Relief Following Medical Cannabis Consumption," and "Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions" published in the journals, Frontiers in Pharmacology and Medicines, respectively, UNM Department of Psychology Associate Professor Jacob Miguel Vigil and UNM Department of Economics Assistant Professor Sarah See Stith, document that patients experienced statistically and clinically significant therapeutic benefits when they used cannabis for symptoms ranging from chronic pain to insomnia.

These studies analyzed data collected with the Releaf App, developed by co-authors Franco Brockelman, Keenan Keeling and Branden Hall and currently, the largest repository of user-entered information on the consumption and effects of cannabis use in the United States with nearly 100,000 recorded user sessions.

Since its release in 2016, the commercially developed Releaf App has been the only publicly available, incentive-free patient educational software program designed for recording how individual cannabis usage sessions correspond to immediate changes in symptom intensity levels and experienced side effects.

This electronic assessment tool enables patients to monitor and manage their cannabis consumption decisions under naturalistic conditions while avoiding the limitations of retrospective survey collection methods (e.g., memory bias, social desirability effects) making it an ideal research tool for measuring real-world cannabis use.

In the first study, across 27 different health conditions with symptoms that ranged from seizure disorders to depression, users reported an average symptom reduction of nearly 4 points on a 1-10 scale following the consumption of cannabis in its various product forms, from concentrates to topicals.

The second study focused specifically on the use of raw natural cannabis flower, or 'buds' for treating insomnia, with similar degrees of effectiveness that varied according to characteristics of the flower and combustion methods. Both investigations were supported in part by the University of New Mexico Medical Cannabis Research Fund, which was designed to facilitate the types of biomedical cannabis-based research that historically have been difficult to fund through conventional governmental entities, such as the National Institutes of Health.

Most prescription medications carry a long list of unavoidable negative side effects and risks of serious health concerns and even death, allowing alternative forms of medication to compete for patient preferences and healthcare industry demands. Medical cannabis is rapidly gaining popularity with the largest expansions in use among older people and patients with significant health conditions.

"Observational studies are more appropriate than experimental research designs for measuring how patients choose to consume cannabis and the effects of those choices," said Vigil. "By collecting massive amounts of patient-entered information on actual cannabis used under real-life circumstances we are able to measure why patients consume cannabis, the types of products that patients use, and the immediate and longer-term effects of such use. In other words, many of the important and practical research questions that randomized controlled trials fail to address."

Cannabis has been investigated as a potential treatment for a wide range of medical conditions from post-traumatic stress disorder to cancer, with the most consistent support for the treatment of chronic pain, epilepsy and spasticity. These studies hint at just how wide cannabis' therapeutic potential may be and are among the first to measure how characteristics of cannabis consumed by millions of people in the U.S. every day are likely to affect different types of health disturbances, both in symptom severity levels and experienced positive and negative side effects.

One of the most striking patterns in the current results was the breadth of symptoms that appeared to improve following cannabis consumption. More than 94 percent of reported symptom intensity reductions following self-administered cannabis use across the various health conditions measured with the Releaf App. This may reflect the ability of the plant's phytocannabinoids to influence the human endocannabinoid system, which regulates both mental and physical health and behavioral systems.

According to the endocannabinoid deficiency theory, many mental and physical health disturbances result from the dysregulation of the body's innate endocannabinoid system (ECS), often described as a master network of chemical signals that promote physical and psychological homeostasis, or biological state-efficiency. The ECS consists of natural ligands (e.g., anandamide and 2-AG) and receptors (CB1 and CB2) that appear to play a major role in efficient regulation of a basic bodily systems including sleep, feeding (e.g., gut permeability and adipogenesis), libido and fertility, pain perception, motivation, happiness, anxiety, learning and memory, social functioning, autoimmune responses, cellular redox, and cancer pathophysiology.

"In other words and unlike conventional pharmaceutical approaches, which largely target specific neurotransmitter sites, cannabis may act to improve a broad spectrum of symptoms by regulating homeostatic functioning, perhaps best described as a system-modulating rather than symptom-modulating form of therapy," said Vigil. "The medicinal potential of this concept and practical application for treating so many and seemingly diverse health conditions is unlike that of any other single medication currently known to exist."

In addition to therapeutic benefits, these studies also showed that cannabis use is associated with frequent and numerous, yet generally non-serious side effects. Positive and context-specific side effects were far more commonly reported than negative side effects by the Releaf App users, with the most frequent reported side effects being positive (relaxed, peaceful, comfy) and the least frequent side effects being negative (paranoid, confused, headache).

Ultimately, cannabis could find a permanent place among our modern repertoire of medication options if it can treat users' more effectively and more safely than conventional pharmaceutical remedies. As in the case of insomnia, prescription sleep aids such as antidepressants (e.g., trazodone, amitriptyline, and doxepin), benzodiazepines (e.g., diazepam and lorazepam), gamma-aminobutyric acid (GABA) medications (zolpidem and eszopiclone), and anti-psychotics (aripiprazole, olanzapine, quetiapine and risperidone) are associated with significant clinical drawbacks and heightened risk of morbidity.

The widespread apparent use of cannabis as a sleep aid and for treating myriad other health symptoms underscores the importance of further medical research regarding its risk-benefit profile and the effectiveness of cannabis as a substitute for other substances, including alcohol, over-the-counter and prescription sleep aids, and scheduled medications (e.g., opioids and sedatives).

According to Stith, "The economic impact of cannabis treatment should also be considered given the current burden of opioid and other high-risk prescriptions on healthcare systems, which have been forced to implement costly modifications to general patient care practices, including prescription monitoring programs, drug screening, and more frequent doctor-patient interactions.

"In addition, if the short-term risk-benefit profile of cannabis found in our studies reflects its longer-term therapeutic potential, substitution of cannabis for traditional pharmaceuticals could reduce the risk of dangerous drug interactions and the costs associated with taking multiple medications by allowing patients to treat a constellation of comorbidities with a single treatment modality. "

"If the results found in our studies can be extrapolated to the general population, could systematically replace multi-billion dollar medication industries around the world. It is likely already beginning to do so," Vigil added.

Explore further: Scientists identify 35 genes associated with cannabis use

More information: Sarah S. Stith et al. Patient-Reported Symptom Relief Following Medical Cannabis Consumption, Frontiers in Pharmacology (2018). DOI: 10.3389/fphar.2018.00916

Jacob Vigil et al. Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions, Medicines (2018). DOI: 10.3390/medicines5030075

Related Stories

Scientists identify 35 genes associated with cannabis use

August 28, 2018
A large-scale genetic study found that some of the same genes associated with the use of cannabis are also associated with certain personality types and psychiatric conditions. The study, published in Nature Neuroscience, ...

Study finds no strong evidence that cannabis reduces chronic pain

July 4, 2018
A four-year study suggests medicinal cannabis is not as effective at relieving chronic non-cancer pain as commonly assumed.

Given the choice, patients will reach for cannabis over prescribed opioids

February 27, 2017
Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research by the University of British Columbia and University of Victoria. ...

Questions remain about the benefits and harms of cannabis

April 3, 2017
Despite dramatic changes in the legal landscape and usage rates of cannabis, evidence is still lacking regarding its potential health and therapeutic effects. Recently, the National Academies of Sciences, Engineering, and ...

Study finds medical cannabis is effective at reducing opioid addiction

November 17, 2017
A new study conducted by researchers at The University of New Mexico, involving medical cannabis and prescription opioid use among chronic pain patients, found a distinct connection between having the legal ability to use ...

Marijuana could help treat drug addiction, mental health

November 16, 2016
Using marijuana could help some alcoholics and people addicted to opioids kick their habits, a UBC study has found.

Recommended for you

Your heart hates air pollution. Portable filters could help

November 13, 2018
Microscopic particles floating in the air we breathe come from sources such as fossil fuel combustion, fires, cigarettes and vehicles. Known as fine particulate matter, this form of air pollution increases the risk of cardiovascular ...

No accounting for these tastes: Artificial flavors a mystery

November 13, 2018
Six artificial flavors are being ordered out of the food supply in a dispute over their safety, but good luck to anyone who wants to know which cookies, candies or drinks they're in.

Simple tips can lead to better food choices

November 13, 2018
A few easily learned tips on eating and food choice can increase amount of healthy food choices between 5 percent and 11 percent, a new Yale University study has found.

Insufficient sleep in children is associated with poor diet, obesity and more screen time

November 13, 2018
A new study conducted among more than 177,000 students suggests that insufficient sleep duration is associated with an unhealthy lifestyle profile among children and adolescents.

New exercise guidelines: Move more, sit less, start younger

November 12, 2018
Move more, sit less and get kids active as young as age 3, say new federal guidelines that stress that any amount and any type of exercise helps health.

Some activity fine for kids recovering from concussions, docs say

November 12, 2018
(HealthDay)—Children and teens who suffer a sports-related concussion should reduce, but not eliminate, physical and mental activity in the days after their injury, an American Academy of Pediatrics report says.

7 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym
5 / 5 (1) Sep 11, 2018
Amateur hour science, this.

Marijuana's miraculous efficacy is probably due to the placebo effect, writ large: people crave a panacea.

How many MORE negative NIST studies will it take to "demystify" this unprofitable treatment regime, if even the brain-dead monkey study in the '70s failed to dampen the public's enthusiasm for marijuana?

(fyi, the brain-dead monkey study was rigged: it wasn't marijuana that killed the monkeys' brains, it was the experimental protocol --- the monkeys were asphyxiated.)
M_Oculus
not rated yet Sep 11, 2018
A drug's efficacy being 'probably due to the placebo effect' is common to many meds. But their toxicity is rarely if ever alleviated by placebo effect. There are countless cases where the benefits a patient feels are overshadowed by painful side-effects.

CBD/THC is touted by patients as effective - whether by placebo or not - yet few report any significant side effects. That's a win win. Aaaand you get to screw over Big Pharma's extortion pricing schemes.
dan42day
not rated yet Sep 11, 2018
The author's of this study concluded by saying that they would have released it last year, but they got high.
shortwave02001
not rated yet Sep 12, 2018
Jamaican scientists have produced many medicines from marijuana which can be got in pharmacies. Cannasol the eye drops for glaucoma has been available over 15 years and a sublingual dosage just became available which uses much less of the active ingredient. Asthmasol for asthma has been available over 5 years now. New drugs for epilepsy and pain just hit the market .Clinical trials were done to prove the effectiveness of the these medications. Cannasol and asthmasol have been have been used for so long that they can be googled.
shortwave02001
not rated yet Sep 12, 2018
There is research in other countries to cure type 1 diabetes with another chemical from marijuana as that chemical causes hypoglycema. I think it the chemical which causes cancer treatment patients to eat. Research is has progressed much further that what can be googled
shortwave02001
not rated yet Sep 12, 2018
Sorry my spelling is bad the first drug developed for glaucoma was Canasol and the sublingual application is I-Cann. Asmasol for asthma. Jamaican scientist Dr. Henry Lowe and his team was responsible for the development of these drugs
Mastoras
not rated yet Sep 12, 2018
Jamaican scientists have produced many medicines from marijuana which can be got in pharmacies. Cannasol the eye drops for glaucoma has been available over 15 years and a sublingual dosage just became available which uses much less of the active ingredient. Asthmasol for asthma has been available over 5 years now. New drugs for epilepsy and pain just hit the market .Clinical trials were done to prove the effectiveness of the these medications. Cannasol and asthmasol have been have been used for so long that they can be googled.


This is an urban myth. This is totally unbased. I've heard the same being said about Kuba: they have found, the myth goes, four cures for cancer. I telephoned to the embassy of Cuba here, at Lefkosia, Zypern (Chypre), and asked whether this is true. They didnt know anything.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.